Transgenic Alzheimer mouse models

Current drug development requires extensive characterization of many compounds and their detailed preclinical analysis. Transgenic mouse models of Alzheimer’s disease have proven valuable tools in the search for drugs and treatments (e.g. vaccines) that can slow down development of AD or eventually cure this disorder. reMYND offers in vivo drug testing in a wide variety of transgenic mouse models, created by LEGTEGG (K.U.Leuven, Belgium), one of its founding laboratories. Alternatively your own mouse model can be tested and characterized by reMYND. For housing, breeding and characterizing transgenic mice, reMYND collaborates with the Medical Research Institute, Warsaw, Poland and with the University of Leuven, Leuven, Belgium. For all services, contact us.

Over the last 3 years, reMYND has signed research agreements with more than 20 biotech and pharma companies located in the US and in more than 10 different European countries.

Our transgenic mice are extensively characterized and represent established preclinical AD models, displaying several aspect of AD :

• amyloid plaques
• cerebral amyloid angiopathy
• microgliosis and astrocytosis
• neurodegeneration
• elevated brain levels of Aβ 40 and Aβ 42
• memory problems as evidenced by water maze and object recognition tests
• increased anxiety and increased aggression

Testing includes :

• biochemical analysis :
  Determination of Aβ 40 and Aβ 42 levels in brain and CSF, APP processing blots, …
• neuropathological analysis :
  immunohistochemistry on β-amyloid, Thioflavin S staining of plaques, quantitation of plaques, microgliosis staining, astrocytosis staining.
• behavioral and memory studies :
  Morris Water Maze, Novel Object Recognition Test, Open Field Test, Isolation-induced Aggression Test, Rotarod, …
• different ways of compound administration are possible (intravenous, intraperitonial, intracerebroventricular, subcutaneous, intramuscular, intranasal, oral, infusion via osmotic pumps…)